Search

Displaying results 5931 - 5940 of 8696 in total
  1. Target

    Transforming growth factor beta activator LRRC32

    go.drugbank.com/bio_entities/BE0014554
    TargetHumans

    Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19651619, PubMed:19750484, PubMed:22278742). As...

    Synonyms: Leucine-rich repeat-containing protein 32Function: receptor ligand inhibitor activity
  2. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.

  3. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).

  4. Drug

    Insulin pork

    go.drugbank.com/drugs/DB00071
    Approved

    Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.

    Categories: Insulins and Analogues for Injection, Fast-Acting, Cytochrome P-450 CYP1A2 Inducers
  5. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo.

  6. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  7. Drug

    IPH 2101

    go.drugbank.com/drugs/DB06049
    Investigational

    IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

  8. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Clenbuterol

    go.drugbank.com/drugs/DB01407
    ApprovedInvestigationalVet approved

    A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.

    Mixtures: EBROMIN-PCategories: Adrenergics for Systemic Use, Cytochrome P-450 Substrates
  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).